Lon­za posts dou­ble-dig­it growth in H1 thanks to strong phar­ma de­mand

Lon­za’s re­cent build­ing spree and con­tracts have the man­u­fac­tur­er look­ing pos­i­tive as it en­ters the sec­ond half of the year.

Ac­cord­ing to Lon­za’s fi­nan­cial re­port for H1, which was re­leased on Fri­day, the Swiss man­u­fac­tur­er post­ed sales of CHF 3 bil­lion, or $3.1 bil­lion, grant­i­ng them a to­tal of 16.8% growth in sales.

The first half’s core EBID­TA for Lon­za al­so rose 33.1% ac­cord­ing to the com­pa­ny. The com­pa­ny is still tar­get­ing low to mid-teen sales and EBID­TA growth for the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER